KR100275174B1 - 면역조정, 항염증제 - Google Patents

면역조정, 항염증제 Download PDF

Info

Publication number
KR100275174B1
KR100275174B1 KR1019940019333A KR19940019333A KR100275174B1 KR 100275174 B1 KR100275174 B1 KR 100275174B1 KR 1019940019333 A KR1019940019333 A KR 1019940019333A KR 19940019333 A KR19940019333 A KR 19940019333A KR 100275174 B1 KR100275174 B1 KR 100275174B1
Authority
KR
South Korea
Prior art keywords
globulin
histamine
agent
added
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940019333A
Other languages
English (en)
Korean (ko)
Other versions
KR950005323A (ko
Inventor
하루오 요시이
유리코 후카타
Original Assignee
고니시 진우에몬
니폰 조키 세야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고니시 진우에몬, 니폰 조키 세야쿠 가부시키가이샤 filed Critical 고니시 진우에몬
Publication of KR950005323A publication Critical patent/KR950005323A/ko
Application granted granted Critical
Publication of KR100275174B1 publication Critical patent/KR100275174B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019940019333A 1993-08-09 1994-08-05 면역조정, 항염증제 Expired - Fee Related KR100275174B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP93-218043 1993-08-09
JP21804393A JP3193205B2 (ja) 1993-08-09 1993-08-09 好酸球増多抑制剤

Publications (2)

Publication Number Publication Date
KR950005323A KR950005323A (ko) 1995-03-20
KR100275174B1 true KR100275174B1 (ko) 2000-12-15

Family

ID=16713756

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940019333A Expired - Fee Related KR100275174B1 (ko) 1993-08-09 1994-08-05 면역조정, 항염증제

Country Status (9)

Country Link
US (1) US5780026A (enExample)
EP (1) EP0646376B1 (enExample)
JP (1) JP3193205B2 (enExample)
KR (1) KR100275174B1 (enExample)
CN (3) CN1127983C (enExample)
AT (1) ATE192655T1 (enExample)
DE (1) DE69424362T2 (enExample)
ES (1) ES2146240T3 (enExample)
TW (1) TW258664B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
IT1278052B1 (it) * 1995-03-14 1997-11-17 Mendes Srl Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
JPH0959180A (ja) * 1995-08-11 1997-03-04 Nippon Zoki Pharmaceut Co Ltd 活性化免疫グロブリン
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
JPH10212246A (ja) 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
JP2000143536A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19944122A1 (de) * 1999-09-15 2001-03-29 Wolfgang Loh Histamin-Immunglobulin-Komplexe zur Behandlung von entzündlichen Erkrankungen bei Säugetieren
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20090317357A1 (en) * 2003-02-24 2009-12-24 Lawrence Steinman Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
EP2142200B1 (en) 2007-05-10 2012-05-16 Rajesh Shah Homeopathy-based formulation
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5585526A (en) * 1978-12-23 1980-06-27 Nippon Zoki Pharmaceut Co Ltd Remedy for allergic disease
US4704273A (en) * 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
US4705685A (en) * 1982-05-17 1987-11-10 Mcmichael John Methods and materials for treatment of disease states involving immunological factors
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US5244902A (en) * 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
IT1237475B (it) * 1989-10-06 1993-06-07 Allergeni modificati chimicamente e procedimento per la loro preparazione
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤

Also Published As

Publication number Publication date
TW258664B (enExample) 1995-10-01
KR950005323A (ko) 1995-03-20
JPH0753406A (ja) 1995-02-28
CN1471974A (zh) 2004-02-04
US5780026A (en) 1998-07-14
CN1471975A (zh) 2004-02-04
EP0646376A1 (en) 1995-04-05
CN1127983C (zh) 2003-11-19
DE69424362D1 (de) 2000-06-15
EP0646376B1 (en) 2000-05-10
JP3193205B2 (ja) 2001-07-30
CN1121430A (zh) 1996-05-01
DE69424362T2 (de) 2000-10-19
ES2146240T3 (es) 2000-08-01
ATE192655T1 (de) 2000-05-15

Similar Documents

Publication Publication Date Title
JP3193205B2 (ja) 好酸球増多抑制剤
US8815245B2 (en) Method of treating viral diseases
WO1987005221A1 (en) Methods and materials for treatment of rheumatoid arthritis
KR100533399B1 (ko) 경구투여용제제
EP0758656B1 (en) Immunoglobulin activated by mixing with a histamine component
Namba et al. Corticotrophin therapy in myasthenia gravis: Effects, indications, and limitations
US6566386B2 (en) Immunomodulating and antiinflammatory agent
KR20000035446A (ko) 세포접착분자 발현억제제
JPH09504792A (ja) 慢性関節リウマチに関する治療
Woodward et al. Periosteal new bone formation in polyarteritis nodosa. A syndrome involving the lower extremities
KR100756974B1 (ko) 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
JP2001348342A (ja) 免疫調整・抗炎症剤
Shingadiya et al. Ayurvedic management of chronic vitiligo (Shvitra): A case study
US4465670A (en) Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor
Hofmann et al. Splenectomy in myasthenia gravis: a therapeutic concept?
US20030118597A1 (en) Process for production of bee venom as pharmaceutical product which can be used effectively in the treatment of rheumatoid arthritis and viral diseases
SU1176899A1 (ru) Способ стимул ции функции коры надпочечников
JPH1053537A (ja) 活性化免疫グロブリン
JPS60209532A (ja) 若年性関節リウマチ治療剤
JPH10279498A (ja) 慢性関節リウマチ治療剤

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20050825

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060920

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060920

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000